Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study Testing the Biologic Activity and Safety of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Stage IV Renal Cell Carcinoma

NCT00272649 is registered in ClinicalTrials.gov with Argos Therapeutics as lead sponsor.

NCT NCT00272649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00272649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study Testing the Biologic Activity and Safety of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Stage IV Renal Cell Carcinoma
Lead sponsor
Argos Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2006
Completion date
February 29, 2012
Enrollment
22 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma